Adage Capital Partners
ENSC icon

Adage Capital Partners’s Ensysce Biosciences ENSC Stock Holding History

Adage Capital Partners’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.6K Hold
149,711
– – ﹤0.01% 941
2025
Q4 		$138K Buy
149,711
+75,000
+100% +$139K ﹤0.01% 888
2025
Q3 		$177K Hold
74,711
– – ﹤0.01% 859
2025
Q2 		$167K Hold
74,711
– – ﹤0.01% 831
2025
Q1 		$191K Buy
74,711
+24,711
+49% +$143K ﹤0.01% 823
2024
Q4 		$407K Buy
+50,000
New +$345K ﹤0.01% 843

Other funds holding ENSC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Adage Capital Partners's ENSC Position: Q1 2026 in Review

Adage Capital Partners held its Ensysce Biosciences (ENSC) position steady in Q1 2026 at 149,711 shares worth $80.6K. The position accounts for ﹤0.01% of the portfolio, ranked #941.

Adage Capital Partners first reported a position in ENSC in Q4 2024 and has held it in 6 quarters since. The position peaked at $407K in Q4 2024. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • Adage Capital Partners held 149,711 shares of Ensysce Biosciences worth $80.6K as of Q1 2026.
  • Adage Capital Partners left its Ensysce Biosciences share count unchanged in Q1 2026.
  • Ensysce Biosciences made up ﹤0.01% of Adage Capital Partners's portfolio in Q1 2026, its #941 holding.
  • Adage Capital Partners first reported a position in Ensysce Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Adage Capital Partners's Ensysce Biosciences position peaked at $407K in Q4 2024.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.